In This Article:
Amid a backdrop of mixed global market performance and heightened trade tensions, Sweden's local market dynamics offer a unique perspective for investors. In such an environment, growth companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those closest to the company's operations and future prospects.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Biovica International (OM:BIOVIC B) | 18.7% | 73.8% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Sileon (OM:SILEON) | 20.3% | 109.3% |
| KebNi (OM:KEBNI B) | 37.8% | 90.4% |
| Yubico (OM:YUBICO) | 37.5% | 43.8% |
| BioArctic (OM:BIOA B) | 34% | 50.9% |
| Calliditas Therapeutics (OM:CALTX) | 11.6% | 52.9% |
| edyoutec (NGM:EDYOU) | 14.6% | 63.1% |
| SaveLend Group (OM:YIELD) | 23.3% | 103.4% |
Let's uncover some gems from our specialized screener.
BioArctic
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (ticker: OM:BIOA B) is a Swedish biopharmaceutical company focused on developing biological drugs for central nervous system disorders, with a market capitalization of approximately SEK 20.67 billion.
Operations: The company generates revenue primarily from its biotechnology segment, totaling SEK 252.21 million.
Insider Ownership: 34%
Return On Equity Forecast: 32% (2027 estimate)
BioArctic, a Swedish biopharma firm, is trading 67.2% below its estimated fair value and shows promising growth indicators with earnings forecasted to grow by 50.87% annually. Despite recent insider activity not indicating substantial buying, the company's return on equity is expected to be robust at 31.7% in three years. Analysts predict a significant price increase of 57.4%. Recent approvals of its Alzheimer’s treatment, Leqembi, in multiple regions including Hong Kong and South Korea highlight its expanding market presence and innovation strength.
-
Take a closer look at BioArctic's potential here in our earnings growth report.
-
Our valuation report here indicates BioArctic may be undervalued.
Sectra
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Sectra AB (publ) specializes in medical IT and cybersecurity solutions across Sweden, the UK, the Netherlands, and other European countries, with a market capitalization of approximately SEK 47.13 billion.
Operations: The company generates revenue primarily from its Imaging IT Solutions and Secure Communications segments, with respective earnings of SEK 2.55 billion and SEK 367.35 million.